Developing antiviral agents that inhibit HCV translation

Information

  • Research Project
  • 6865461
  • ApplicationId
    6865461
  • Core Project Number
    R44AI054029
  • Full Project Number
    5R44AI054029-03
  • Serial Number
    54029
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/24/2003 - 21 years ago
  • Project End Date
    2/28/2006 - 18 years ago
  • Program Officer Name
    WOLPERT, MARY K
  • Budget Start Date
    3/1/2005 - 19 years ago
  • Budget End Date
    2/28/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    3
  • Suffix
  • Award Notice Date
    3/29/2005 - 19 years ago
Organizations

Developing antiviral agents that inhibit HCV translation

DESCRIPTION (provided by applicant): It is estimated that over 170 million people are infected by hepatitis C virus (HCV) worldwide. Currently, there are limited therapeutic agents and no vaccine available for HCV infection. Thus, it is necessary to develop new anti-HCV drugs. HCV is a member of the family Flaviviridae. The HCV genome contains a long, single open reading frame mRNA that encodes the viral proteins. An internal ribosome entry site (IRES) cis-acting element was identified in the 5' untranslated region of the HCV RNA, which directs translation initiation of the viral proteins. The HCV IRES has conserved primary sequences, unique secondary and tertiary structures, and a distinct interaction mode with cellular initiation factors. Based on our expertise in drug discovery, i.e. targeting Post-Transcription-Control, we are pursuing HCV IRES-mediated translation initiation against HCV infection. Using HCV IRES translation assays established at PTC, we have identified low molecular weight lead compounds that are selective against HCV IRES-mediated translation. The goal of the application is to perform lead optimization for improving the activity, selectivity, cytotoxicity and pharmacological properties of these compounds. A successful outcome of the proposed studies will be the identification of a development candidate(s) that acts on HCV IRES-facilitated translation initiation.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    652409
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:652409\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PTC THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOUTH PLAINFIELD
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07080
  • Organization District
    UNITED STATES